Charles E Mowbray

List of Publications by Year
in descending order

43	1,873	304743 22	265206 42
papers	citations	h-index	g-index

48	48	48	2818
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 719.	12.8	86
2	Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2. EBioMedicine, 2022, 82, 104148.	6.1	8
3	2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling. PLoS Neglected Tropical Diseases, 2021, 15, e0009196.	3.0	8
4	Film-Forming Systems for the Delivery of DNDI-0690 to Treat Cutaneous Leishmaniasis. Pharmaceutics, 2021, 13, 516.	4.5	11
5	Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series. Microorganisms, 2021, 9, 1408.	3.6	8
6	Collaborative virtual screening to elaborate an imidazo[1,2-a]pyridine hit series for visceral leishmaniasis. RSC Medicinal Chemistry, 2021, 12, 384-393.	3.9	17
7	DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 16159-16176.	6.4	31
8	Structure-activity relationship of 4-azaindole-2-piperidine derivatives as agents against Trypanosoma cruzi. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126779.	2.2	6
9	Introduction to the themed collection on â€˜Neglected tropical diseasesâ€™. RSC Medicinal Chemistry, 2020, 11, 1098-1099.	3.9	2
10	Hit-to-lead optimization of a benzene sulfonamide series for potential antileishmanial agents. RSC Medicinal Chemistry, 2020, 11, 1267-1274.	3.9	5
11	Pharmacokinetics and Pharmacodynamics of the Nitroimidazole DNDI-0690 in Mouse Models of Cutaneous Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	25
12	Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 106-117.	3.4	58
13	Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 11, 129-138.	3.4	44
14	Drug Discovery for Kinetoplastid Diseases: Future Directions. ACS Infectious Diseases, 2019, 5, 152-157.	3.8	78
15	In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series. International Journal for Parasitology: Drugs and Drug Resistance, 2018, 8, 81-86.	3.4	38
16	Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 207-213.	2.2	22
17	Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives. Clinical Microbiology Reviews, 2018, 31, .	13.6	145
18	Chapter 2. Anti-leishmanial Drug Discovery: Past, Present and Future Perspectives. RSC Drug Discovery Series, 2017, , 24-36.	0.3	7

#	Article	IF	Citations
19	Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity. Journal of Medicinal Chemistry, 2015, 58, 9615-9624.	6.4	52
20	Hit and lead criteria in drug discovery for infectious diseases of the developing world. Nature Reviews Drug Discovery, 2015, 14, 751-758.	46.4	437
21	Treatment options for second-stage gambiense human African trypanosomiasis. Expert Review of Anti-Infective Therapy, 2014, 12, 1407-1417.	4.4	84
22	The role of modern drug discovery in the fight against neglected and tropical diseases. MedChemComm, 2014, 5, 688.	3.4	44
23	The discovery and profile of PF-0868087, a CNS-sparing histamine H3 receptor antagonist for the treatment of allergic rhinitis. MedChemComm, 2012, 3, 339-343.	3.4	5
24	Synthesis of novel histamine H4 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1156-1159.	2.2	16
25	Comparison of the Nonâ€Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers. Chemical Biology and Drug Design, 2011, 77, 393-397.	3.2	22
26	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structureâ€“activity relationship (SAR). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6591-6595.	2.2	6
27	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: A novel histamine H4 receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6596-6602.	2.2	32
28	Lersivirine, a Nonnucleoside Reverse Transcriptase Inhibitor with Activity against Drug-Resistant Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy, 2010, 54, 4451-4463.	3.2	56
29	Discovery of a small molecule inhibitor through interference with the gp120â€“CD4 interaction. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5246-5249.	2.2	11
30	Pyrazole NNRTIs 1: Design and initial optimisation of a novel template. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5599-5602.	2.2	29
31	Pyrazole NNRTIs 3: Optimisation of physicochemical properties. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5603-5606.	2.2	29
32	Pyrazole NNRTIs 4: Selection of UK-453,061 (lersivirine) as a Development Candidate. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5857-5860.	2.2	95
33	Novel Indazole Non-Nucleoside Reverse Transcriptase Inhibitors Using Molecular Hybridization Based on Crystallographic Overlays. Journal of Medicinal Chemistry, 2009, 52, 1219-1223.	6.4	49
34	Optimization of 5-Aryloxyimidazole Non-Nucleoside Reverse Transcriptase Inhibitors. ChemMedChem, 2008, 3, 1756-1762.	3.2	13
35	Small, non-peptide C5a receptor antagonists: Part 2. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5605-5608.	2.2	8
36	Small, non-peptide C5a receptor antagonists: Part 1. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5601-5604.	2.2	17

#	Article	IF	Citations
37	A Concise and Selective Synthesis of Novel 5-Aryloxyimidazole NNRTIs. Organic Letters, 2006, 8, 1725-1727.	4.6	17
38	A Concise Synthesis of Trifluoromethyl-Substituted 4-Aryloxy Pyrazoles. Synlett, 2006, 2006, 1404-1406.	1.8	8
39	Structureâ^'Activity Relationships of 1,4-Dihydro-(1H,4H)-quinoxaline-2,3-diones as N-Methyl-d-aspartate (Glycine Site) Receptor Antagonists. 1. Heterocyclic Substituted 5-Alkyl Derivatives. Journal of Medicinal Chemistry, 2001, 44, 1951-1962.	6.4	77
40	Title is missing!. Journal of Chemical Crystallography, 1999, 29, 335-341.	1.1	4
41	Concise Synthesis of Enantiomerically Pure Phenylalanine, Homophenylalanine, and Bishomophenylalanine Derivatives Using Organozinc Chemistry:â€‰ NMR Studies of Amino Acid-Derived Organozinc Reagents. Journal of Organic Chemistry, 1998, 63, 7875-7884.	3.2	106
42	Polycycle construction via cascade radical fragmentation transannulation-cyclisation processes. Tetrahedron Letters, 1993, 34, 127-130.	1.4	53
43	Synthesis of some semi-synthetic nemadectins. Journal of the Chemical Society Perkin Transactions 1, 1990, , 1813.	0.9	4